We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Circulating Progenitor Cell Traffic Reflects Blood Vessel Repair

By LabMedica International staff writers
Posted on 18 Dec 2019
Print article
Image: The BD FACSAria III fluorescent activated cell sorter used to enumerate circulating progenitor cells (Photo courtesy of Becton, Dickinson and Company.
Image: The BD FACSAria III fluorescent activated cell sorter used to enumerate circulating progenitor cells (Photo courtesy of Becton, Dickinson and Company.
Identifying patients with otherwise stable coronary artery disease (CAD) who are high-risk and would benefit from more intense or invasive interventions is currently a major theme in cardiology studies.

In healthy people, physical exercise causes the cells to leave the bone marrow and enter the blood, because their job is repairing blood vessels. In people with coronary artery disease whose arteries are narrowed enough so that they develop ischemia (restriction of blood flow); more of the cells are diverted to the heart to repair the damage.

Medical Scientists from the Emory University School of Medicine (Atlanta, GA, USA) carried out a prospective cohort study included a population-based sample of 454 patients with stable CAD who were recruited between June 1, 2011, and August 15, 2014, and followed up for three years. Data were analyzed from September 15, 2018, to October 15, 2018. The patients were divided into two groups, based on whether circulating progenitor cells (CPC) counts increased or decreased during a treadmill exercise test. Circulating progenitor cells were enumerated with flow cytometry as CD34-expressing mononuclear cells (CD45med/CD34+), with additional quantification of subsets co-expressing the chemokine (C-X-C motif) receptor 4 (CD34+/CXCR4+).

The team reported that of the 454 patients (mean age ± SD, 63±9 years; 76% men) with stable CAD enrolled in the study, 142 (31.3%) had stress-induced ischemia and 312 (68.7%) did not, as measured by single-photon emission computed tomography. During stress testing, patients with stress-induced ischemia had a mean decrease of 20.2% (interquartile range [IQR], −45.3 to 5.5) in their CD34+/CXCR4+ counts, and patients without stress-induced ischemia had a mean increase of 3.2% (IQR, −20.6 to 35.1) in their CD34+/CXCR4+ counts. Twenty-four patients (5.2%) experienced adverse events.

Kasra Moazzami, MD, MPH, a cardiologist, and the first author of the study said, “A fall in CPC count after exercise appears to be an independent determinant of high risk in patients with stable coronary artery disease, even after adjusting for known clinical risk factors. The information gained from the changes in CPC counts during exercise may be more useful to cardiologists in risk stratifying these patients than the treadmill exercise test itself.”

The authors concluded that patients with CAD, a decrease in CPC counts during exercise is associated with a worse disease prognosis compared with the presence of stress-induced myocardial ischemia. The study was published on December 4, 2019 in the journal JAMA Cardiology.

Related Links:
Emory University School of Medicine

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.